CTLA4 and central nervous system cancer: The results showed that the upregulation of PLEKHA4 expression was significantly related to PD-1/PD-L1, CTLA4, and TIM-3 in glioma, indicating that targeting PLEKHA4 may improve immunotherapy in glioma.